AbbVie Inc. has announced results from the Viti-Up clinical studies, which evaluated upadacitinib as a potential systemic treatment for patients with non-segmental vitiligo (NSV). The Viti-Up program comprised two replicate Phase 3 studies, designed to assess the efficacy, safety, and tolerability of upadacitinib 15 mg once daily compared to placebo in adults and adolescents aged 12 years and older eligible for systemic therapy. Participants were randomized in a 2:1 ratio to receive either upadacitinib or placebo over a 48-week period. Study results have already been presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CG77050) on February 03, 2026, and is solely responsible for the information contained therein.